 Thirty patients will be enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome MDS patients with iron overload. Patients enrolled in this study will have low or intermediate INT-1 risk MDS per International Prognostic Scoring System IPSS criteria. All patients will initiate treatment with 20mgkgday deferasirox. 